+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the use of stereotactic radiotherapy SRT as a treatment strategy for patients with oligoprogressive metastatic renal cell carcinoma RCC who are already undergoing systemic therapies. This phase II study focuses on patients whose cancer has progressed in a limited number of sites despite ongoing treatment, aiming to control local tumors and delay the need for additional systemic therapies. The study builds on evidence that SRT can effectively target RCC metastases and may also stimulate the immune system when combined with immunotherapy. The study involves delivering high-dose stereotactic radiotherapy to metastatic sites showing progression in patients receiving systemic therapies such as targeted drugs or immunotherapy. Eligible patients have 1 to 3 progressing metastases in up to 2 organs, with lesions measuring 4 cm or less, and will continue their current systemic treatment while receiving SRT either concurrently or sequentially. This approach aims to locally control progressing tumors and potentially extend the effectiveness of ongoing therapy. Participants will undergo imaging assessments to confirm disease progression and measure tumor response, with follow-up visits to monitor tumor control and treatment side effects. Researchers will evaluate progression-free survival six months after randomization as the primary outcome, along with local and overall control rates and treatment-related adverse events. The study includes monitoring for safety and effectiveness up to 12 months post-treatment, with participants involvement lasting until at least one month after treatment completion.

Age: 18Years +All GendersPhase 2
30 locations
E

Actively Recruiting

Researchers are studying the effectiveness and safety of lorlatinib in patients with untreated ALK-positive non-small-cell lung carcinoma NSCLC. This research is conducted in a French real-world setting and sponsored by Pfizer. The study aims to assess how lorlatinib performs as a treatment option for this specific type of lung cancer. Participants will receive lorlatinib as a single-agent oral treatment at a dose of 100 mg daily. The study is designed as a single-group trial where patients continuously take lorlatinib. The treatment and observation period includes assessments up to 25 months, during which various outcomes such as progression-free survival, overall survival, response rates, and treatment duration will be evaluated. During the study, participants will be monitored regularly with imaging tests like CT scans and brain MRIs before starting treatment. Researchers will track treatment adherence, symptom changes, adverse events, and resistance mechanisms. Patient-reported outcomes and quality of life questionnaires will be collected at multiple time points up to 48 months. Safety and effectiveness measures will guide the ongoing evaluation, with follow-up visits scheduled throughout the study period.

Age: 18Years +All GendersPhase Not Applicable
32 locations
P

Actively Recruiting

Researchers are evaluating whether adding local consolidative radiotherapy to the standard treatment improves overall survival in patients with metastatic urothelial bladder cancer. This study focuses on patients who have no disease progression and have no more than three remaining distant metastatic lesions after completing first-line systemic therapy. It is a Phase II, randomized, open-label study conducted at multiple centers. Participants will be randomly assigned either to receive standard care alone or to receive consolidative radiotherapy targeting the pelvis andor metastatic sites in addition to standard care. Some patients may have had a previous bladder tumor resection. The radiotherapy is given after the initial systemic treatment phase, which includes chemotherapy andor immunotherapy. The study follows patients for four years from the time of randomization. During the study, patients will have regular assessments including imaging scans to check disease status, toxicity evaluations according to national criteria, and quality of life questionnaires using the EORTC QLQ-C-30 tool. Researchers will monitor overall survival and progression-free survival over four years. Patients must be able to participate and agree to follow the study procedures, and safety is closely observed throughout the trial.

Age: 18Years +All GendersPhase 2
20 locations
C

Actively Recruiting

The TEMPOS-GEniToUrinary Group GETUG study is a multicenter, medico-economic trial comparing two radiation treatmentsbrachytherapy and stereotactic body radiotherapy SBRTin men with low and intermediate risk prostate cancer. The study particularly focuses on erectile dysfunction as a key outcome. Researchers aim to evaluate the cost-utility of SBRT compared to standard Iodine 125 brachytherapy over a period of three years after treatment, including secondary analyses on cost-effectiveness and quality of life up to five years. Participants are assigned to one of two treatment groups. The experimental group receives SBRT delivering 7.25 Gy per fraction, given in five doses for a total of 36.25 Gy to the prostate. Fiducials are implanted in the prostate to help guide treatment using Cyberknife or a conventional linear accelerator with tracking systems. The control group receives brachytherapy with Iodine 125, delivering a total dose of 144 Gy to the prostate. The study includes long-term follow-up to assess erectile dysfunction, genito-urinary and gastro-intestinal toxicities, and quality of life up to five years after treatment. Participants will undergo monitoring and assessments throughout the study period, including evaluations of erectile dysfunction and other side effects. The main outcome measured is the incremental cost-utility ratio comparing SBRT to brachytherapy at three years, with further health economic evaluations at five years. The trial plans to recruit about 240 men across multiple centers over two years, with ongoing data collection on treatment impact, side effects, and quality of life to inform future treatment recommendations and health insurance budgeting.

Age: 18Years +MALEPhase Not Applicable
20 locations
E

Actively Recruiting

Researchers are evaluating whether a personalized rehabilitation program that combines nutrition, physiotherapy, and physical activity, started early in the intensive care unit ICU and continued through hospital discharge and at home, can improve long-term outcomes for patients who have undergone invasive mechanical ventilation and vasopressor therapy. This trial compares this early extended rehabilitation approach to usual care, which involves standard nutritional support and physiotherapy provided according to local ICU practices. Participants will be randomly assigned to either the individualized rehabilitation group or the usual care group. The rehabilitation group will receive a tailored program involving dieticians, physiotherapists, and physical activity instructors, with the intervention continuing for 12 weeks from ICU admission through post-ICU wards and at home. The usual care group will receive standard nutritional and physiotherapy support from day 0 to day 180. Throughout the study, participants will undergo various assessments including physical activity levels, muscle strength, muscle mass, body weight, and quality of life measured at multiple time points up to 12 months after randomization. The primary outcome is the distance walked in six minutes at 6 months. Researchers will also track mortality rates, glucose control, insulin usage, infection rates, and hospital stay lengths. The total participation may last up to 12 months with follow-up evaluations during this period.

Age: 18Years +All GendersPhase Not Applicable
52 locations
S

Actively Recruiting

In intensive care units, patients often need central venous catheters for care and safe medication delivery, but these devices can lead to infections. Most prevention focuses on how catheters are inserted and handled, but the length of time the catheter stays in place is a main source of infection. This research compares changing infusion sets every 7 days versus every 4 days to see if less frequent changes increase infection risk while considering impacts on nursing workload and costs. The study involves two groups one where infusion sets connected to the catheter are replaced every 7 days, and another where they are replaced every 4 days, the current standard recommendation. Each replacement involves disconnecting old sets and replacing them with new sterile ones. Both procedures are performed by qualified nurses during the patients ICU stay. Participants are adult ICU patients with a central venous catheter placed less than 72 hours ago and expected to remain for at least 7 days. Researchers will monitor infections related to the catheter from insertion until 48 hours after removal, along with bloodstream infections, catheter colonization, ICU length of stay, mortality, nursing time, and replacement costs. The study follows patients up to 90 days to collect these outcomes and assess the effects of the different replacement schedules.

Age: 18Years +All GendersPhase Not Applicable
27 locations
A

Actively Recruiting

Bronchiectasis is a chronic lung condition where parts of the airways are permanently widened, causing mucus buildup, infections, and ongoing inflammation. This study evaluates the long-term use of the SIMEOX medical device at home, combined with remote physiotherapy, to improve quality of life and reduce lung flare-ups in adults with non-cystic fibrosis bronchiectasis. The research compares this approach to enhanced standard care including remote physiotherapy alone. Participants will be randomly assigned to either standard care with remote physiotherapy or to use the SIMEOX device daily at home alongside remote physiotherapy. Remote physiotherapy sessions occur once a month for the first three months and then every three months. The study spans an average of 24 months to assess the effects of adding the SIMEOX device to usual care. During the study, participants will complete quality of life questionnaires and undergo lung function tests at 6, 12, and 24 months. The main outcomes measured include the yearly rate of lung exacerbations and changes in quality of life scores. Researchers will also track hospitalizations, treatment compliance, adverse events, and lung function changes. The long follow-up aims to evaluate the sustained impact of the device and physiotherapy on participants respiratory health.

Age: 18Years +All GendersPhase Not Applicable
57 locations
N

Actively Recruiting

Researchers are studying patients with metastatic colorectal cancer to identify clinical and biological factors that predict how well fruquintinib works in real-world settings. The study aims to confirm survival and safety results seen in previous trials and to better understand treatment outcomes, especially in older patients aged 70 and above, who have been underrepresented in earlier research. This cohort is designed to optimize treatment pathways by pinpointing patients who may benefit most from fruquintinib. Participants will receive fruquintinib, an oral drug that targets specific blood vessel growth receptors, given as 5 mg daily for 21 days followed by a 7-day break. This cycle repeats until the cancer progresses, unacceptable side effects occur, the patient dies, or the patient chooses to stop treatment. The study includes patients treated under compassionate use or after marketing authorization in France, integrating routine clinical practice data. During the study, participants will be monitored for overall survival up to one year after starting treatment, which is the main outcome measured. Additional monitoring includes progression-free survival within the same timeframe. The study involves collecting biological samples like circulating tumor DNA and tumor tissue blocks. Safety, survival, and treatment response data will be gathered to support understanding of fruquintinibs effects in everyday clinical use. The study is expected to continue until the end of 2031.

Age: 18Years +All GendersPhase Not Applicable
83 locations
P

Actively Recruiting

Researchers are investigating personalized treatments for patients with endometrial cancer based on their molecular profiles. This study, part of the RAINBO program, focuses on patients with p53 abnormal endometrial cancer who have completed standard adjuvant chemoradiation therapy. The goal is to see if maintenance treatment with the drug Olaparib can improve recurrence-free survival compared to observation alone. Participants are randomly assigned to either receive Olaparib at a dose of 300 mg twice daily for one year or to be closely observed without additional treatment. All patients have undergone surgery and sequential radiotherapy and chemotherapy, typically following the PORTEC-3 regimen or similar local protocols. The study monitors patients over a three-year period to assess the primary outcome of recurrence-free survival. During the study, participants will have regular assessments including tumor evaluations, organ function tests, and overall health monitoring to ensure safety and treatment adherence. Researchers will also collect data on side effects and disease status throughout the treatment and follow-up periods. The total participation time extends up to three years, including the one-year treatment or observation phase and subsequent monitoring.

Age: 18Years +FEMALEPhase 3
15 locations